Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 232-242

  Liu, Xiyong ^a   Wang, Sean K ^a   Zhang, Keqiang ^a   Zhang, Hang ^a   Pan, Qin ^b   Liu, Zhiwei ^b   Pan, Hongming ^b   Xue, Lijun ^a   Yen, Yun ^a,c   Chu, Peiguo G ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GALECTIN 4; GLUCURONOSYLTRANSFERASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYPICAN 3; MESSENGER RNA; MICRORNA; MICRORNA 657; PROTEIN; RETINOIC ACID INDUCED GENE E; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; GLYPICAN; GPC3 PROTEIN, HUMAN; MIRN657 MICRORNA, HUMAN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CARCINOGENESIS; GENETICS; KAPLAN MEIER METHOD; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VIROLOGY;

AGED; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RNA, MESSENGER;

EID: 84928201463     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu245     Document Type: Article

References (54)

1. Akagi, G. et al. (1984) Liver cell dysplasia and hepatitis B surface antigen in liver cirrhosis and hepatocellular carcinoma. Cancer, 54, 315-318.
2. Okuda, K. et al. (1982) Hepatocellular carcinoma arising in noncirrhotic and highly cirrhotic livers: a comparative study of histopathology and frequency of hepatitis B markers. Cancer, 49, 450-455.
3. Le, B.B. et al. (1995) Adenomatous hyperplasia in cirrhotic livers: histological evaluation, cellular density, and proliferative activity of 35 macronodular lesions in the cirrhotic explants of 10 adult French patients. Hum. Pathol., 26, 897-906.
4. Sakamoto, M. et al. (1991) Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum. Pathol., 22, 172-178.
5. Takayama, T. et al. (1990) Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet, 336, 1150-1153.
6. Borzio, M. et al. (1995) Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology, 108, 812-817.
7. Cohen, C. et al. (1979) Liver cell dysplasia: association with hepatocellular carcinoma, cirrhosis and hepatitis B antigen carrier status. Cancer, 44, 1671-1676.
8. Le, B.B. et al. (1997) Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J. Hepatol., 27, 835-842.
9. Anthony, P.P. et al. (1973) Liver cell dysplasia: a premalignant condition. J. Clin. Pathol., 26, 217-223.
10. Watanabe, S. et al. (1983) Morphologic studies of the liver cell dysplasia. Cancer, 51, 2197-2205.
11. Park, Y.N. et al. (2006) Large liver cell dysplasia: a controversial entity. J. Hepatol., 45, 734-743.
12. Ikeda, H. et al. (2009) Large cell change of hepatocytes in chronic viral hepatitis represents a senescent-related lesion. Hum. Pathol., 40, 1774-1782.
13. Jia, H.L. et al. (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin. Cancer Res., 13, 1133-1139.
14. Skawran, B. et al. (2008) Gene expression profiling in hepatocellular carcinoma: upregulation of genes in amplified chromosome regions. Mod. Pathol., 21, 505-516.
15. Kondoh, N. et al. (1999) Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res., 59, 4990-4996.
16. Hoshida, Y. et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med., 359, 1995-2004.
17. Filmus, J. et al. (2001) Glypicans: proteoglycans with a surprise. J. Clin. Invest., 108, 497-501.
18. Nakatsura, T. et al. (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun., 306, 16-25.
19. Yamauchi, N. et al. (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod. Pathol., 18, 1591-1598.
20. Kandil, D.H. et al. (2009) Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv. Anat. Pathol., 16, 125-129.
21. Capurro, M. et al. (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 125, 89-97.
22. Wang, X.Y. et al. (2006) Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum. Pathol., 37, 1435-1441.
23. Di Tommaso, L. et al. (2007) Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology, 45, 725-734.
24. Libbrecht, L. et al. (2006) Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am. J. Surg. Pathol., 30, 1405-1411.
25. Zhu, Z.W. et al. (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 48, 558-564.
26. Zynger, D.L. et al. (2006) Glypican 3: a novel marker in testicular germ cell tumors. Am. J. Surg. Pathol., 30, 1570-1575.
27. Coston, W.M. et al. (2008) Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am. J. Surg. Pathol., 32, 433-444.
28. Anthony, P.P. et al. (1977) The morphology of cirrhosis: definition, nomenclature, and classification. Bull. World Health Organ., 55, 521-540.
29. Abdul-Al, H.M. et al. (2008) Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum. Pathol., 39, 209-212.
30. Subramanian, A. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A., 102, 15545-15550.
31. Zhang, L. et al. (2013) MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology, 57, 1919-1930.
32. Lee, J.S. et al. (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet., 36, 1306-1311.
33. Lee, D.C. et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res., 68, 4210-4220.
34. Tsuji, M. et al. (1999) An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol. Int., 49, 310-317.
35. Koelma, I.A. et al. (1986) Hepatocellular carcinoma, adenoma, and focal nodular hyperplasia. Comparative histopathologic study with immunohistochemical parameters. Arch. Pathol. Lab. Med., 110, 1035-1040.
36. Ganne-Carrié, N. et al. (1996) Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology, 23, 1112-1118.
37. Wang, H.L. et al. (2008) Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch. Pathol. Lab. Med., 132, 1723-1728.
38. Llovet, J.M. et al. (2006) A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology, 131, 1758-1767.
39. Tornillo, L. et al. (2002) Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab. Invest., 82, 547-553.
40. Grozdanov, P.N. et al. (2006) The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab. Invest., 86, 1272-1284.
41. Midorikawa, Y. et al. (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int. J. Cancer, 103, 455-465.
42. Capurro, M.I. et al. (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res., 65, 6245-6254.
43. Filmus, J. et al. (2008) Glypicans. Genome Biol., 9, 224.
44. Ueno, K. et al. (2011) IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int. J. Cancer, 129, 2360-2369.
45. Zhu, W. et al. (2008) IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature, 454, 345-349.
46. Satelli, A. et al. (2011) Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int. J. Cancer, 129, 799-809.
47. Abrahams, N.A. et al. (2004) Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology, 45, 593-602.
48. Kao, J.H. et al. (2000) Overview of hepatitis B and C viruses. In Goedert, J.J. (ed) Infectious Causes of Cancer. Human Press, NJ, pp. 313-330.
49. Zaman, S.N. et al. (1985) Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet, 1, 1357-1360.
50. Fattovich, G. et al. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127, S35-S50.
51. Ostapowicz, G. et al. (1998) Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology, 27, 1730-1735.
52. Chang, M.H. et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med., 336, 1855-1859.
53. Kasprzak, A. et al. (2008) Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol. Res., 38, 1-26.
54. Feng, M. et al. (2013) Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A., 110, E1083-E1091.